Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,596 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Allogeneic Transplant Clear all

Conditions: Gingival Recession
Interventions: Tunneled coronally advanced flap; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Allogenic Stem Cell Transplantation, Myeloid Malignancies, Lymphoid Malignancies, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: agenT-797; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
Interventions: Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D); Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Effect of Ultraviolet Radiation on Photoaged Skin, Dermatologic Disorders
Interventions: Allogeneic Mesenchymal Bone Marrow Cells; Biological
Lead sponsor: Stemedica Cell Technologies, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 2
States / cities: La Mesa, California • San Diego, California

Conditions: Cell Transplantation
Interventions: Medical Chart Review, Monitoring Device, Physical Therapy; Other · Device · Procedure
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders, Cerebral Adrenoleukodystrophy, Inherited Metabolic Disorders
Interventions: Blood and Marrow Transplant; Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 0 Years to 25 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
Interventions: CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine; Device · Procedure · Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: Up to 74 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Graft Failure, Poor Graft Function
Interventions: CD34+ Selected Donor Cell Boost, Blood Stem Cell Infusion; Device · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: CD34+ cells selected with the Miltenyi Clinimacs machine; Device
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 6 Months to 17 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome, Fanconi Anemia, Previously Treated Myelodysplastic Syndrome
Interventions: Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Total-Body Irradiation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 4
States / cities: Oakland, California • Nashville, Tennessee • Seattle, Washington + 1 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: Busulfan, Clofarabine, Allogeneic Stem Cell Infusion; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT)
Interventions: Reduced-Intensity Conditioning Regimen, Myeloablative Conditioning Regimen; Drug
Lead sponsor: Randy Windreich; Other
Eligibility: 0 Months to 26 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Myelogenous Leukemia, Multiple Myeloma, Non Hodgkin's Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia
Interventions: CD8 Depleted Donor Lymphocyte; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: Imatinib Mesylate, Fludarabine (Fludara), Busulfan, Antithymocyte Globulin (ATG), Tacrolimus, Methotrexate, Donor lymphocyte infusion (DLI), Stem Cell Transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bone Marrow Transplant- Autologous or Allogeneic
Interventions: Breastmilk; Dietary Supplement
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 5 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: IDH1 Mutation Myeloid Neoplasms
Interventions: Ivosidenib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Columbus, Ohio

Conditions: Lymphoma, B-Cell, Lymphoma, Non-hodgkins
Interventions: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 73 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Microbial Colonization
Interventions: Rifaximin; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 21 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hematologic Malignancy, Hematopoietic/Lymphoid Cancer, Blood Cancer
Interventions: Positive Psychology Intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: COVID-19 Vaccination; Biological
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 2,206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Hemoglobinopathies, Sickle Cell Disease, Thalassemia
Interventions: Busulfex, Fludarabine, Alemtuzumab, Stem Cell Transfusion; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 6
States / cities: Atlanta, Georgia • Shreveport, Louisiana • Boston, Massachusetts + 1 more

Conditions: Viral Infections After HSCT
Interventions: VSTs; Biological
Lead sponsor: Catherine Bollard; Other
Eligibility: 4 Weeks to 45 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
Interventions: filgrastim, allogeneic bone marrow transplantation; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Nashville, Tennessee • Seattle, Washington

Conditions: Osteodysplasia
Interventions: Marrow stromal cell infusion; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Treatment of Gingival Recession Defects Using Platelet-Rich Fibrin With an Allogenic Dermal Matrix

Allogeneic iNKT Cell Therapy (agenT-797) After SCT

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging

Prescribed Physical Activity in Improving Sleep and Physical Performance in Patients Undergoing Stem Cell Transplant

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure

Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

Human Breastmilk in Children Receiving a Bone Marrow Transplant

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation

A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Allogeneic Virus-specific T Cell Lines (VSTs)

Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease

Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation